Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249379 · ClinicalTrials.gov registry record · Phase 4
Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT00249379: Clinical Trial Phase 4 study, sponsored by Virginia Commonwealth University.
NCT00249379 is a Phase 4 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00249379, a Phase 4 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to test how tolerable and effective acamprosate is when used to prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in drug court).
Primary Outcome
Number of participants using alcohol and other drugs during 12 weeks
Interventions
- DRUG Acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Why NCT00249379 stopped before completion
NCT00249379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Acamprosate is the first listed.
NCT00249379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00249379 about?
NCT00249379 is a clinical study titled "Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees". The purpose of this study is to test how tolerable and effective acamprosate is when used to prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in drug court).
What is the current status of trial NCT00249379?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2005-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00249379?
The interventions under investigation include: Acamprosate (DRUG).
Who is sponsoring clinical trial NCT00249379?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00249379's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia